Abstract
Patients with nonalcoholic fatty liver disease (NAFLD) often have hyperlipidemia and are at a higher risk of cardiovascular disease (CVD).1 As first-line lipid-lowering drugs, statins are widely used for primary and secondary CVD prevention.2 However, there have been concerns about statins underprescription for patients with NAFLD because of fear of hepatoxicity.3 We aimed to describe and compare the pattern of statins use before and after CVD events in patients with NAFLD with the general population.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
